Nyxoah is trading at $1.41, up 10.6%, as healthcare stocks gain amid renewed biotechnology optimism, acquisition activity, and a supportive regulatory backdrop.

  • No new company-specific announcement was identified for September 25, 2026.
  • Nyxoah’s latest official release was the September 21 CFO transition.
  • The September 7 BREATHE-study update is not a same-day catalyst.